Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company
developing MultiStem® (invimestrocel) for critical care
indications, announced today their participation in two October
conferences, the 2022 Cell & Gene Meeting on the Mesa on
October 11-13, 2022 and the 14th World Stroke Congress on October
26-29, 2022.
Dr. Robert W. Mays, Executive Vice President and Head of
Regenerative Medicine & Neuroscience, will present live at the
2022 Cell & Gene Meeting on the Mesa in Carlsbad, California on
October 11. Dr. Mays will provide a corporate overview of the
Company’s therapeutic MultiStem® cellular therapy, and an update on
preclinical and clinical perspectives utilizing the MultiStem
cellular platform technology to date. The presentation will provide
an overview of the Company’s ongoing clinical studies in ischemic
stroke, acute respiratory distress syndrome and trauma. Mr. Dan
Camardo, Chief Executive Officer, Ms. Maia Hansen, Chief Operating
Officer, and Dr. Sarah Busch, Vice President of Regenerative
Medicine and Head of Non-Clinical Development, will also be in
attendance from October 11-13 to meet with registered
attendees.
Organized by the Alliance for Regenerative Medicine, the Cell
& Gene Meeting on the Mesa is a three-day conference that
brings together senior executives and top decision-makers in the
industry to highlight technical and clinical achievements over the
past 12 months in the areas of cell therapy, gene therapy, gene
editing, tissue engineering and broader regenerative medicine
technologies.
The following are specific details regarding the Athersys
presentation at the Cell & Gene Meeting on the Mesa
conference:
Event:
The 2022 Cell & Gene Meeting
on the Mesa
Date:
Tuesday, October 11, 2022
Time:
4:00 PM Pacific Time
Location:
Oxford Biomedica Ballroom, Park
Hyatt Aviara Resort, Carlsbad, CA
A live video webcast of all company presentations and sessions
will be available for registered participants and will also be
published on the conference website after the event concludes. In
addition, a webcast of the corporate presentation by Dr. Mays will
be posted on the investor section of www.athersys.com when it
becomes available. Please visit www.meetingonthemesa.com for
detailed conference information and registration.
Additionally, Dr. Mays will be attending the 14th World Stroke
Congress on October 26-29 to meet virtually with global
professionals and stroke specialists to discuss the latest science,
clinical trials, breakthroughs, and guidelines to stroke
prevention. The hybrid Congress is organized by the World Stroke
Organization, whose mission is to reduce the global burden of
stroke through prevention, treatment and long-term care. Please
visit https://worldstrokecongress.org/ for additional information
and registration.
About Athersys
Athersys is a biotechnology company engaged in the discovery and
development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing
its MultiStem cell therapy product, a patented, adult-derived
“off-the-shelf” stem cell product, initially for disease
indications in the neurological, inflammatory and immune, and other
critical care indications and has several ongoing clinical trials
evaluating this potential regenerative medicine product. Athersys
has forged strategic partnerships and a broad network of
collaborations to further advance MultiStem cell therapy toward
commercialization. Investors and others should note that we may
post information about the Company on our website at
www.athersys.com and/or on our accounts on Twitter, Facebook,
LinkedIn or other social media platforms. It is possible that the
postings could include information deemed to be material
information. Therefore, we encourage investors, the media and
others interested in the Company to review the information we post
on our website at www.athersys.com and on our social media
accounts. Follow Athersys on Twitter at www.twitter.com/athersys.
Information that we may post about the Company on our website
and/or on our accounts on Twitter, Facebook, LinkedIn or other
social media platforms may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainties. You should not place
undue reliance on forward-looking statements contained on our
website and/or on our accounts on Twitter, Facebook, LinkedIn or
other social media platforms, and we undertake no obligation to
publicly update forward-looking statements, whether as a result of
new information, future events or otherwise.
About MultiStem
MultiStem (invimestrocel) cell therapy is a patented
regenerative medicine product in clinical development that has
shown the ability to promote tissue repair and healing in a variety
of ways, such as through the production of therapeutic factors in
response to signals of inflammation and tissue damage. MultiStem
therapy’s potential for multidimensional therapeutic impact
distinguishes it from traditional biopharmaceutical therapies
focused on a single mechanism of benefit. The therapy represents a
unique "off-the-shelf" stem cell product that can be manufactured
in a scalable manner, may be stored for years in frozen form, and
is administered without tissue matching or the need for immune
suppression. Based upon its efficacy profile, its novel mechanisms
of action, and a favorable and consistent tolerability demonstrated
in clinical studies, we believe that MultiStem therapy could
provide a meaningful benefit to patients, including those suffering
from serious diseases and conditions with unmet medical need.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. These forward-looking
statements relate to, among other things, statements regarding the
potential benefits of our MultiStem product candidate; anticipated
results of clinical trials involving our MultiStem product
candidate; the expected timetable for development of our product
candidates, our growth strategy, and our future financial
performance, including our operations, economic performance,
financial condition, prospects, and other future events. We have
attempted to identify forward-looking statements by using such
words as “anticipates,” “believes,” “can,” “continue,” “could,”
“estimates,” “expects,” “intends,” “may,” “plans,” “potential,”
“should,” “suggest,” “will,” or other similar expressions. These
forward-looking statements are only predictions and are largely
based on our current expectations. A number of known and unknown
risks, uncertainties, and other factors could affect the accuracy
of these statements. The following risks and uncertainties may
cause our actual results, levels of activity, performance, or
achievements to differ materially from any future results, levels
of activity, performance, or achievements expressed or implied by
these forward-looking statements: the possibility of unfavorable
results from ongoing and additional clinical trials involving
MultiStem; the risk that positive results in a clinical trial may
not be replicated in subsequent or confirmatory trials or success
in an early stage clinical trial may not be predictive of results
in later stage or large scale clinical trials; our ability to raise
capital to fund our operations in the near term, including, but not
limited to, our ability to raise financing and to continue as a
going concern; our ability to enter into a partnership for the
co-development and co-commercialization of MultiStem; our ability
to successfully implement our transformation plan, including our
ability to reduce expenses; and the risks mentioned elsewhere in
our Annual Report on Form 10-K for the year ended December 31, 2021
under Item 1A, “Risk Factors” and our other filings with the SEC.
You should not place undue reliance on forward-looking statements,
and we undertake no obligation to publicly update forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221004005735/en/
Athersys Ellen Gurley Manager of Corporate Communications
and Investor Relations ir@athersys.com
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2024 to May 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From May 2023 to May 2024